INVO - INVO sees Q4 revenue above analysts estimates
2023-03-31 09:13:06 ET
- INVO Bioscience ( NASDAQ: INVO ) said it expects Q4 total revenue to reflect a sequential increase of approximately 15% to 19%, or to between $270K and $280K, above analysts estimate of $257.50K.
- "Looking forward, we are thrilled with the March 2023 signing of binding purchase agreements for our first IVF clinic acquisition, the March 2023 closing of our registered direct offering generating approximately $3 million in gross proceeds, as well as the continued progress and revenue growth in early 2023 for our INVO Center clinics."
- Press Release
For further details see:
INVO sees Q4 revenue above analysts estimates